These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16502500)

  • 1. A case of acute ventricular capture threshold rise associated with flecainide acetate.
    Kang TS; Yoon YW; Park S; Hong BK; Kim D; Kwon HM; Kim HS
    Yonsei Med J; 2006 Feb; 47(1):152-4. PubMed ID: 16502500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute loss of capture due to flecainide acetate.
    Antonelli D; Freedberg NA; Rosenfeld T
    Pacing Clin Electrophysiol; 2001 Jul; 24(7):1170. PubMed ID: 11475838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.
    Apps A; Miller CP; Fellows S; Jones M
    BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26286909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate.
    Fornieles-Pérez H; Montoya-García M; Levine PA; Sanz O
    Pacing Clin Electrophysiol; 2002 May; 25(5):871-2. PubMed ID: 12049386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture.
    Suffredini JM; Rutland J; Akpunonu P; Baum R; Catanzaro J; Elayi CS
    Am J Case Rep; 2019 Aug; 20():1279-1283. PubMed ID: 31467262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
    Rienstra M; Wiesfeld AC; van Veldhuisen DJ; van Gelder IC
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1027-31. PubMed ID: 16715868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased capture threshold in permanent His-bundle pacing associated with flecainide.
    Jiang M; Wasserlauf J; Knight BP; Verma N
    Pacing Clin Electrophysiol; 2020 Apr; 43(4):360-363. PubMed ID: 32010978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.
    Hellestrand KJ; Burnett PJ; Milne JR; Bexton RS; Nathan AW; Camm AJ
    Pacing Clin Electrophysiol; 1983 Sep; 6(5 Pt 1):892-9. PubMed ID: 6195608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia.
    Ohki R; Takahashi M; Mizuno O; Fujikawa H; Mitsuhashi T; Katsuki T; Ikeda U; Shimada K
    Pacing Clin Electrophysiol; 2001 Jan; 24(1):119-21. PubMed ID: 11227957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical case of the month. Atrial flutter with rapid ventricular response (1:1 atrioventricular conduction) caused by flecaïnide].
    Robinet S; Melon R; Piérard L
    Rev Med Liege; 2007 Dec; 62(12):701-3. PubMed ID: 18286943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
    Kawabata M; Hirao K; Horikawa T; Suzuki K; Motokawa K; Suzuki F; Azegami K; Hiejima K
    J Electrocardiol; 2001 Jan; 34(1):65-72. PubMed ID: 11239374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
    Maison-Blanche P; Brembilla-Perrot B; Fauchier JP; Babuty D; Garnier LF; Rouesnel P; Breuillac JC; Funck F; Scheck F; Peraudeau P; Medvedowsky JL
    Ann Cardiol Angeiol (Paris); 1997 Feb; 46(2):109-16. PubMed ID: 9137677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference by antiarrhythmic agents with function of electrical cardiac devices.
    Tworek DA; Nazari J; Ezri M; Bauman JL
    Clin Pharm; 1992 Jan; 11(1):48-56. PubMed ID: 1730178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proarrhythmic Antiarrhythmic.
    Pollet M; Saeed M
    Tex Heart Inst J; 2016 Dec; 43(6):507-508. PubMed ID: 28100969
    [No Abstract]   [Full Text] [Related]  

  • 18. [Flecainide acetate].
    Bordier P; Garrigue S; Clémenty J
    Ann Cardiol Angeiol (Paris); 1996 May; 45(5):263-79. PubMed ID: 8763646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pacemaker malfunction induced by a pharmaco-metabolic "perfect storm": a brief report.
    Rodriguez MA; Helms E; Shubert J; Pavri BB
    J Clin Pharmacol; 2011 Jan; 51(1):107-9. PubMed ID: 20357296
    [No Abstract]   [Full Text] [Related]  

  • 20. Flecainide causing elevated capture thresholds on pacemaker implantation.
    Leow KC; Lim WY; Lee A; Rahman M; Tan R
    BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38514158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.